http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 16 Feb 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html <p> ROANOKE, Va.--(BUSINESS WIRE)-- Luna Innovations Incorporated (OTCMKTS: LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260216383469r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en" style="width:0;height:0" /><span class="bwct31415" /></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on <a target="_blank" href="http://businesswire.com">businesswire.com</a>: </span><span id="mmgallerylink-link"><a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></span></p> <p> <b>Investor Contact</b>: <br></br>Ryan Stewart, General Counsel <br></br>Luna Innovations Incorporated <br></br>Phone: (540) 769-8400 <br></br>Email: <a target="_blank" rel="nofollow" href="mailto:stewartr@lunainc.com" shape="rect">stewartr@lunainc.com</a> </p> <p>Source: Luna Innovations Incorporated</p> http://www.streetinsider.com/Press+Releases/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html Mon, 16 Feb 2026 08:00:00 -0400 LUNA O.00167028 http://www.streetinsider.com/Press+Releases/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html <p> ROANOKE, Va.--(BUSINESS WIRE)-- Luna Innovations Incorporated (OTCMKTS: LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260216383469r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en" style="width:0;height:0" /><span class="bwct31415" /></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on <a target="_blank" href="http://businesswire.com">businesswire.com</a>: </span><span id="mmgallerylink-link"><a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></span></p> <p> <b>Investor Contact</b>: <br></br>Ryan Stewart, General Counsel <br></br>Luna Innovations Incorporated <br></br>Phone: (540) 769-8400 <br></br>Email: <a target="_blank" rel="nofollow" href="mailto:stewartr@lunainc.com" shape="rect">stewartr@lunainc.com</a> </p> <p>Source: Luna Innovations Incorporated</p> http://www.streetinsider.com/Press+Releases/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html Mon, 16 Feb 2026 08:00:00 -0400 LUNA O.00167028 http://www.streetinsider.com/Business+Wire/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html <p> ROANOKE, Va.--(BUSINESS WIRE)-- Luna Innovations Incorporated (OTCMKTS: LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260216383469r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en" style="width:0;height:0" /><span class="bwct31415" /></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on <a target="_blank" href="http://businesswire.com">businesswire.com</a>: </span><span id="mmgallerylink-link"><a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></span></p> <p> <b>Investor Contact</b>: <br></br>Ryan Stewart, General Counsel <br></br>Luna Innovations Incorporated <br></br>Phone: (540) 769-8400 <br></br>Email: <a target="_blank" rel="nofollow" href="mailto:stewartr@lunainc.com" shape="rect">stewartr@lunainc.com</a> </p> <p>Source: Luna Innovations Incorporated</p> http://www.streetinsider.com/Business+Wire/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html Mon, 16 Feb 2026 08:00:00 -0400 LUNA O.00167028 http://www.streetinsider.com/Business+Wire/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html <p> ROANOKE, Va.--(BUSINESS WIRE)-- Luna Innovations Incorporated (OTCMKTS: LUNA), a global leader in advanced fiber-optic technology, today announced a Notice of Pendency and Proposed Settlement of Stockholder Derivative Action. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></p><p><img alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260216383469r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en" style="width:0;height:0" /><span class="bwct31415" /></p><p id="mmgallerylink"><span id="mmgallerylink-phrase">View source version on <a target="_blank" href="http://businesswire.com">businesswire.com</a>: </span><span id="mmgallerylink-link"><a target="_blank" href="https://www.businesswire.com/news/home/20260216383469/en/" rel="nofollow">https://www.businesswire.com/news/home/20260216383469/en/</a></span></p> <p> <b>Investor Contact</b>: <br></br>Ryan Stewart, General Counsel <br></br>Luna Innovations Incorporated <br></br>Phone: (540) 769-8400 <br></br>Email: <a target="_blank" rel="nofollow" href="mailto:stewartr@lunainc.com" shape="rect">stewartr@lunainc.com</a> </p> <p>Source: Luna Innovations Incorporated</p> http://www.streetinsider.com/Business+Wire/Luna+Innovations+Incorporated+-+Notice+of+Pendency+and+Proposed+Settlement+of+Stockholder+Derivative+Action/26003582.html Mon, 16 Feb 2026 08:00:00 -0400 LUNA O.00167028 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+ROYCE+%26amp%3B+ASSOCIATES+LP/25898942.html si-local-file:///var/storage/secattach/20260127/25898942.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+ROYCE+%26amp%3B+ASSOCIATES+LP/25898942.html Tue, 27 Jan 2026 12:42:00 -0400 LUNA O.00167028 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+ROYCE+%26amp%3B+ASSOCIATES+LP/25898942.html si-local-file:///var/storage/secattach/20260127/25898942.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+ROYCE+%26amp%3B+ASSOCIATES+LP/25898942.html Tue, 27 Jan 2026 12:42:00 -0400 LUNA O.00167028 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+WASATCH+ADVISORS+LP/24780507.html si-local-file:///var/storage/secattach/20250512/24780507.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+WASATCH+ADVISORS+LP/24780507.html Mon, 12 May 2025 16:13:00 -0400 LUNA O.00167028 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+WASATCH+ADVISORS+LP/24780507.html si-local-file:///var/storage/secattach/20250512/24780507.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++LUNA+INNOVATIONS+INC+++++++++++++++++++Filed+by%3A+WASATCH+ADVISORS+LP/24780507.html Mon, 12 May 2025 16:13:00 -0400 LUNA O.00167028 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/Press+Releases/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939 http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html <div class="xn-content"> <p><span class="legendSpanClass">VALBY, <location value="LC/dk" idsrc="xmltag.org" >Denmark</location></span>, <span class="legendSpanClass"><chron>March 10, 2025</chron></span> /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).</p> <p>H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>.<br/><br/>The ODD in <location value="LC/jp" idsrc="xmltag.org" >Japan</location> adds to other important designations: the SAKIGAKE designation by <location value="LC/jp" idsrc="xmltag.org" >Japan's</location> MHLW in <chron>March 2023</chron>, the Orphan Drug Designation (ODD) by the <span value="ACORN:0682203466" idsrc="xmltag.org" >US http://www.streetinsider.com/PRNewswire/Lundbeck%27s+potential+treatment+for+Multiple+System+Atrophy+granted+Orphan+Drug+Designation+in+Japan/24474050.html Mon, 10 Mar 2025 04:23:00 -0400 A.06822034 A.50213550 HLUNA HLUNB LUNA LUNB O.00293698 O.20026344 O.35229939